Cardinal Health, Inc. — Form 8-K Summary
Report date: October 1, 2026. This is a current-event filing, not a periodic financial report; it does not provide financial statements for a reporting period.
Business context
Cardinal Health announced that it entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. The filing does not provide further terms of the proposed extension.
Financial metrics and outlook
- The company reaffirmed fiscal 2027 non-GAAP EPS guidance of $12.40 to $12.60.
- It also reaffirmed long-term non-GAAP EPS growth guidance of 12% to 14%.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other current-period financial figures.
Changes, risks, and unusual items
The disclosed development is the binding letter of intent with CVS Health and the reaffirmation of previously issued guidance. The filing text does not specify agreement economics, conditions to completion, risks, or any change to the guidance assumptions.
Key facts for investors to verify
- Review Exhibit 99.1 for the full announcement and any additional terms of the CVS Health agreement extension.
- Confirm the status and completion of the binding letter of intent and the final agreement terms.
- Review the assumptions and risks underlying fiscal 2027 EPS and long-term EPS growth guidance.